NDC 55513-224

Riabni

Rituximab-arrx

Riabni is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Rituximab.

• Product ID: 55513-224_2710bdd3-d741-4092-82cc-d4e5bd893993
• NDC: 55513-224
• Product Type: Human Prescription Drug
• Proprietary Name: Riabni
• Generic Name: Rituximab-arrx
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2021-01-06
• Marketing Category: BLA / BLA
• Application Number: BLA761140
• Labeler Name: Amgen Inc
• Substance Name: RITUXIMAB
• Active Ingredient Strength: 100 mg/10mL
• Pharm Classes: CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 55513-224-01

1 VIAL, SINGLE-DOSE in 1 CARTON (55513-224-01) > 10 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2021-01-06
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Riabni" or generic name "Rituximab-arrx"

NDC	Brand Name	Generic Name
55513-224	Riabni	rituximab-arrx
55513-326	Riabni	rituximab-arrx